[IMCAS Asia 2026 Special ⑥ | Symposium] VIOL Medical Hosts SYLFIRM X APAC Symposium in Bangkok, Sharing an Asia-Pacific Clinical Framework for Dual-Wave RF
On the eve of IMCAS Asia 2026, on June 18, VIOL Medical held the SYLFIRM X APAC Symposium in Bangkok 2026 at the Siam Kempinski Hotel, where key opinion leaders (KOLs) from Korea, Malaysia, and Thailand shared clinical strategies spanning pigmentation, vascular concerns, skin rejuvenation, and selected complication-management scenarios, centered on the dual-wave RF microneedling platform SYLFIRM X. Rather than approaching these concerns as separate treatment categories, the speakers converged on a shared idea: that clinical outcomes hinge less on output intensity alone than on how precisely tissue responses are tailored—through the selection of PW or CW mode, treatment depth, and energy level, together with planned combinations with lasers and skin boosters, according to lesion depth, skin type, and the amount of downtime a patient is willing to accept. In a session moderated by Dr. Lim Ting Song of Malaysia, Dr. Arim Min of Korea (Min&Min Clinic) framed SYLFIRM X as a "core device" in multimodal practice, describing a sequence in which an injectable booster is given first, the skin is cleansed, and SYLFIRM X is then applied with a topical booster, while Dr. Edmond Lau of Malaysia presented three cases illustrating its clinical scope—recalcitrant melasma, vascular toning, and a PDLLA nodule case. Prof. Niwat Polnikorn of Thailand framed the discussion as "beyond an output race, toward mechanism," presenting proposed mechanisms of dual-wave RF and reporting a mean MSI reduction of 49.7% in a 16-case series of recalcitrant melasma.
#MedicalAestheticNews #VIOLMedical #SYLFIRMX #DrArimMin #MinandMinClinic #DrEdmondLau #ProfNiwatPolnikorn #DrLimTingSong
★ Article Link: https://www.medicalaestheticnews.com/news/articleView.html?idxno=20094


Comments
Post a Comment